Corcept Therapeutics (CORT) Phase 3 ROSELLA ovarian cancer trial succeeds

Rhea-AI Filing Summary

Corcept Therapeutics announced that ROSELLA, its pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint. This means the treatment combination achieved its main goal of improving how long patients live in this hard-to-treat setting. The company shared this outcome through a press release attached as an exhibit, signaling a key late-stage milestone for relacorilant in oncology.

Insights

Biopharma clinical and regulatory analyst

Phase 3 ROSELLA success is a pivotal, thesis-changing milestone.

Corcept Therapeutics reported that ROSELLA, its pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, met the overall survival primary endpoint. Overall survival is typically the most important outcome in late-stage oncology studies, so success here represents a major de‑risking event for this program. The result positions relacorilant as a potentially meaningful option in a population with limited treatment choices.

Because the trial is described as pivotal and Phase 3, this outcome can form the backbone of a potential marketing application, subject to full data, safety profile and regulatory review. The filing does not provide numerical survival data or timelines for next steps, so the ultimate impact will depend on details likely contained in the referenced press release and in future disclosures. Nonetheless, meeting a Phase 3 overall survival endpoint in this indication is a clearly positive development for Corcept’s pipeline and strategic outlook.

CORCEPT THERAPEUTICS INC false 0001088856 0001088856 2026-01-22 2026-01-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

January 22, 2026

Date of Report (date of earliest event reported)

Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

Delaware		000-50679		77-0487658
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

101 Redwood Shores Parkway, Redwood City, CA 94065

(Address of Principal Executive Offices) (Zip Code)

(650) 327-3270

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CORT		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On January 22, 2026, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing that ROSELLA, the Company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibits No.		Description
99.1		Press Release of Corcept Therapeutics Incorporated, January 22, 2026
104.1		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				CORCEPT THERAPEUTICS INCORPORATED
Date: January 22, 2026				By:		/s/ Atabak Mokari
				Name:		Atabak Mokari
				Title:		Chief Financial Officer

FAQ

What did Corcept Therapeutics (CORT) announce in this 8-K?

Corcept Therapeutics reported that ROSELLA, its pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, met its overall survival primary endpoint.

What is the ROSELLA trial mentioned by Corcept Therapeutics (CORT)?

ROSELLA is a pivotal Phase 3 clinical trial evaluating relacorilant in combination with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer.

Which endpoint did Corcept’s ROSELLA Phase 3 trial achieve?

The ROSELLA trial met its primary endpoint of overall survival, indicating the treatment regimen improved how long patients live compared with control, as designed in the study.

What disease setting is targeted in Corcept’s ROSELLA Phase 3 trial?

ROSELLA targets patients with platinum-resistant ovarian cancer, a group whose disease has progressed despite prior platinum-based chemotherapy.

How did Corcept Therapeutics communicate the ROSELLA trial results?

Corcept issued a press release dated January 22, 2026, which is included as Exhibit 99.1 and incorporated by reference in the 8-K.

Does this 8-K describe detailed ROSELLA Phase 3 data for Corcept (CORT)?

The 8-K states that the trial met its overall survival primary endpoint and refers readers to the press release in Exhibit 99.1 for additional information.